Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis

Intensive Care Med. 2022 Jun;48(6):770-771. doi: 10.1007/s00134-022-06648-7. Epub 2022 Feb 18.

Authors

Shodai Yoshihiro¹, Shunsuke Taito^{2

3}

Affiliations

¹ Pharmaceutical Department, JA Hiroshima General Hospital, 1-3-3 Jigozen, Hatsukaichi-shi, Hiroshima, 738-8503, Japan. shodaidotnet@gmail.com.
² Division of Rehabilitation, Department of Clinical Practice and Support, Hiroshima University Hospital, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
³ Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan.

PMID: 35182165
DOI: 10.1007/s00134-022-06648-7

No abstract available

Publication types

Letter
Comment

MeSH terms

Anti-Bacterial Agents / therapeutic use
Drug Monitoring*
Drug Therapy, Combination
Humans
Penicillanic Acid / therapeutic use
Piperacillin / therapeutic use
Piperacillin, Tazobactam Drug Combination / therapeutic use
Sepsis* / drug therapy

Substances

Anti-Bacterial Agents
Piperacillin, Tazobactam Drug Combination
Penicillanic Acid
Piperacillin